European Expedited Programs & Harnessing HTA

Regulators from the European Medicines Agency are paying close attention to the UK’s fledgling but “incredible” innovative licensing and access pathway (ILAP), which aims to speed up access to medicines with greater alignment between regulatory and health technology assessment (HTA) processes, heard delegates at a regulatory symposium. The EMA also acknowledged that it could “do better” when it comes to engaging with HTA bodies to ensure that its expedited program, the PRIME (priority medicines) scheme, delivers patient access to medicines more quickly.

By operating a scheme that is run by regulators and HTA bodies, the UK is “doing something incredible” with the ILAP, which operates as a partnership between the UK medicines regulator, the MHRA, and the HTA bodies in England